March 27, 2012
Cumberland Pharmaceuticals Inc.
(Nasdaq: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that Chief Executive Officer
will present at the Needham Life Sciences Conference in
2:00 p.m. Eastern Time
Tuesday, April 3, 2012
. Mr. Kazimi will provide an update on the Company and its 2012 strategy.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology.
's product portfolio includes Acetadote® (
) Injection for the treatment of acetaminophen poisoning, Caldolor® (
) Injection, the first injectable treatment for pain and fever approved in
the United States
, and Kristalose® (
) for Oral Solution, a prescription laxative.
is dedicated to providing innovative products that improve quality of care for patients. For more information on
, please visit the Company's website at
This press release contains forward-looking statements, which are subject to certain risks and reflect
's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of
's operations are subject to factors outside its control, and any one or combination of these factors could materially affect
's results of operations. These factors include market conditions, competition, an inability of manufacturers to produce
's products on a timely basis or a failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure and other factors discussed in the Company's 2010 Annual Report on Form 10-K filed with the SEC on
March 11, 2011
. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.
SOURCE Cumberland Pharmaceuticals Inc.